Literature DB >> 1560325

Medium-chain triglycerides in formula for preterm neonates: implications for hepatic and extrahepatic metabolism.

P R Borum1.   

Abstract

Medium-chain fatty acids are an important energy source for preterm neonates. Based on assumptions from earlier investigations, 40% to 60% of fatty acids in formula designed for preterm neonates are C6:0 to C12:0. This review will reevaluate these assumptions about C6:0 to C12:0 fatty acids. More recent investigations have indicated that when C6:0 to C12:0 fatty acids are administered in high concentrations, they are metabolized in several tissues by carnitine-dependent mechanisms. Incomplete oxidation of C6:0 to C12:0 fatty acids may result in elevated dicarboxylic acid levels. Feeding formulas high in C6:0 to C12:0 fatty acids has not improved nitrogen retention or growth of preterm neonates. Current data indicate that the fatty acid profiles of formula for preterm neonates are not optimal. Optimization of the fatty acid profile in the diet awaits an improved understanding of the metabolism of fatty acids of all chain lengths in the preterm neonate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560325     DOI: 10.1016/s0022-3476(05)81248-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  3 in total

1.  Prenatal diagnosis of a defect in medium-chain fatty acid oxidation.

Authors:  R J Pollitt; N J Manning; S E Olpin; I D Young
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

Review 2.  Role Medium-Chain Fatty Acids in the Lipid Metabolism of Infants.

Authors:  Tinglan Yuan; Lei Wang; Jun Jin; Lijuan Mi; Jinzhu Pang; Zhengdong Liu; Jinyan Gong; Cong Sun; Jufang Li; Wei Wei; Qingzhe Jin; Xingguo Wang
Journal:  Front Nutr       Date:  2022-06-09

3.  Developing intestine is injured during absorption of oleic acid but not its ethyl ester.

Authors:  O R Velasquez; A R Place; P Tso; K D Crissinger
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.